44 related articles for article (PubMed ID: 23998617)
1. [Relationship between Spred1 and acute myeloid leukemia].
Zhang Y; Li Y; Zhang R
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):1083-7. PubMed ID: 23998617
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Study of Aberrant CpG Island Hypermethylation of
Sun J; Zhang J; Wang Y; Li Y; Zhang R
Int J Med Sci; 2019; 16(2):324-330. PubMed ID: 30745814
[No Abstract] [Full Text] [Related]
3. The Sprouty-related protein, Spred, inhibits cell motility, metastasis, and Rho-mediated actin reorganization.
Miyoshi K; Wakioka T; Nishinakamura H; Kamio M; Yang L; Inoue M; Hasegawa M; Yonemitsu Y; Komiya S; Yoshimura A
Oncogene; 2004 Jul; 23(33):5567-76. PubMed ID: 15184877
[TBL] [Abstract][Full Text] [Related]
4. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
[TBL] [Abstract][Full Text] [Related]
5. The neurofibromin recruitment factor Spred1 binds to the GAP related domain without affecting Ras inactivation.
Dunzendorfer-Matt T; Mercado EL; Maly K; McCormick F; Scheffzek K
Proc Natl Acad Sci U S A; 2016 Jul; 113(27):7497-502. PubMed ID: 27313208
[TBL] [Abstract][Full Text] [Related]
6.
Zhang R; Zhang Y; Lu X; Xu W; Wang H; Mo W; Pang H; Tang R; Li S; Yan X; Li Y
Front Oncol; 2020; 10():204. PubMed ID: 32175275
[TBL] [Abstract][Full Text] [Related]
7. Methylation of SPRED1: A New Target in Acute Myeloid Leukemia.
Su N; Wang Y; Lu X; Xu W; Wang H; Mo W; Pang H; Tang R; Li S; Yan X; Li Y; Zhang R
Front Oncol; 2022; 12():854192. PubMed ID: 35359401
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the receptor FGFRL1 with the negative regulator Spred1.
Zhuang L; Villiger P; Trueb B
Cell Signal; 2011 Sep; 23(9):1496-504. PubMed ID: 21616146
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and acute myeloid leukemia.
Haouas H
Hematology; 2014 Sep; 19(6):311-23. PubMed ID: 24192539
[TBL] [Abstract][Full Text] [Related]
10. NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.
Führer S; Ahammer L; Ausserbichler A; Scheffzek K; Dunzendorfer-Matt T; Tollinger M
Biomol NMR Assign; 2017 Oct; 11(2):305-308. PubMed ID: 28831766
[TBL] [Abstract][Full Text] [Related]
11. Tribbles-1 and -2 are tumour suppressors, down-regulated in human acute myeloid leukaemia.
Gilby DC; Sung HY; Winship PR; Goodeve AC; Reilly JT; Kiss-Toth E
Immunol Lett; 2010 May; 130(1-2):115-24. PubMed ID: 20005259
[TBL] [Abstract][Full Text] [Related]
12. Review and update of SPRED1 mutations causing Legius syndrome.
Brems H; Pasmant E; Van Minkelen R; Wimmer K; Upadhyaya M; Legius E; Messiaen L
Hum Mutat; 2012 Nov; 33(11):1538-46. PubMed ID: 22753041
[TBL] [Abstract][Full Text] [Related]
13. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.
Brems H; Chmara M; Sahbatou M; Denayer E; Taniguchi K; Kato R; Somers R; Messiaen L; De Schepper S; Fryns JP; Cools J; Marynen P; Thomas G; Yoshimura A; Legius E
Nat Genet; 2007 Sep; 39(9):1120-6. PubMed ID: 17704776
[TBL] [Abstract][Full Text] [Related]
14. Spred1, a negative regulator of Ras-MAPK-ERK, is enriched in CNS germinal zones, dampens NSC proliferation, and maintains ventricular zone structure.
Phoenix TN; Temple S
Genes Dev; 2010 Jan; 24(1):45-56. PubMed ID: 20047999
[TBL] [Abstract][Full Text] [Related]
15. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles.
Jansen F; Yang X; Hoelscher M; Cattelan A; Schmitz T; Proebsting S; Wenzel D; Vosen S; Franklin BS; Fleischmann BK; Nickenig G; Werner N
Circulation; 2013 Oct; 128(18):2026-38. PubMed ID: 24014835
[TBL] [Abstract][Full Text] [Related]
16. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
18. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect.
Cristóbal I; Garcia-Orti L; Cirauqui C; Alonso MM; Calasanz MJ; Odero MD
Leukemia; 2011 Apr; 25(4):606-14. PubMed ID: 21233840
[TBL] [Abstract][Full Text] [Related]
19. Role of RhoA inactivation in reduced cell proliferation of human airway smooth muscle by simvastatin.
Takeda N; Kondo M; Ito S; Ito Y; Shimokata K; Kume H
Am J Respir Cell Mol Biol; 2006 Dec; 35(6):722-9. PubMed ID: 16858009
[TBL] [Abstract][Full Text] [Related]
20. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
